Artiva biotherapeutics to present longer-term phase 1/2 data for allonk® in combination with rituximab in patients with b-cell-non-hodgkin lymphoma at the asgct 28th annual meeting

Prolonged duration of response, deep b-cell depletion, and well-tolerated safety profile support the potential of allonk® + rituximab for the treatment of b-cell driven diseases in a community setting

ARTV Ratings Summary

ARTV Quant Ranking